Ultragenyx Pharmaceutical Inc at JPMorgan Healthcare Conference Transcript
Everyone, my name is Matthew Holt, and I'm part of the JPM Biotech equity research team. It's my pleasure to introduce our next presenting company, Ultragenyx Pharmaceuticals. Presenting for Ultragenyx today will be the CEO and President, Emil Kakkis. And please note that following the presentation -- or it's actually at 1:30, there will be a breakout session in the Olympic room, which is to the left.
So with that, I'll hand it over to you.
Thanks very much and good afternoon, everyone. I'm happy to be here to give you an update on Ultragenyx. This is our legal warning. Company now, I think, 2020, just coming close to 10 years from founding, is really positioned for significant value of growth. We have strong revenue drivers, with the Crysvita franchise, which is growing at exceptional rate in addition to other products, in fact, we expect to have 3 products and 4 indications approved later this year
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
